Sanofi’s Phase 3 CIDP Failure Hits Riliprubart and Raises Doubts for Dianthus’ Claseprubart

Sanofi discontinues its Phase 3 MOBILIZE study of riliprubart in refractory CIDP after failing to show efficacy. The setback raises major doubts for Dianthus’ claseprubart (C1s inhibitor).